Poland· PL-100495909
Ryzneuta
A efbemalenograstim alfa product containing efbemalenograstimum alfa, registered in Poland by Fisiopharma S.r.l.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Efbemalenograstim alfa is registered in 9 of 19 countries.
Countries holding a registration under ATC L03AA18 (efbemalenograstim alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Efbemalenograstim alfa · ATC L03AA18
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Efbemalenograstimum alfa
- Manufacturer
- Fisiopharma S.r.l.
- Country
- Poland (PL)
- ATC code
- L03AA18
- ATC class
- Efbemalenograstim alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991609535
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efbemalenograstim alfa in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRyzneuta 20 mgFisiopharma
- CzechiaRYZNEUTAFISIOPHARMA S.R.L., NUCLEO INDUSTRIALE, PALOMONTE
- IcelandRyzneutaEvive Biotechnology Ireland Limited
- SwedenRyzneuta 20 mg Injektionsvätska, lösning i förfylld sprutaFisiopharma S.r.l.
- FinlandRyzneutaFisiopharma S.r.l.
- IrelandRyzneuta 20 mg solution for injectionFisiopharma SrL
- NetherlandsRyzneuta 20 mg oplossing voor injectieFisiopharma S.r.L.
- United StatesRYZNEUTAAcrotech Biopharma Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ryzneuta
- Liechtenstein · Ryzneuta
- Norway · Ryzneuta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6b6a2343-620a-496a-a532-e95faed6b72a GET /v1/drugs/6b6a2343-620a-496a-a532-e95faed6b72a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "20 mg",
"packaging": "05909991609535 ¦ Rpz ¦ EU/1/24/1793/001 ¦ 154172\n1 amp.-strzyk. 1 ml",
"substance": "Efbemalenograstimum alfa 20 mg",
"common_name": "Efbemalenograstimum alfa",
"pl_product_id": "100495909",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about efbemalenograstim alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.